secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001493152-26-014156
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaPro subsidiary reports $472K net loss for six months; going concern risk
----------------------------------------------------------------------------

- BriaPro net loss widened to $472,231 for six months ended Jan 31, 2026 vs $233,185 a year ago.
- Accumulated deficit $1.65M; negative working capital $1.64M; cash only $1.
- Going concern: dependent on parent BriaCell for financing; material uncertainty noted.
- On Feb 18, 2026, BriaPro agreed to acquire sCD80 license from BriaCell for cancer therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315226014156/0001493152-26-014156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315226014156/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-014156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer